Xrcc1 arg399gln polymorphism and bladder cancer risk: Updated meta-analyses based on 5767 cases and 6919 controls

Experimental Biology and Medicine

Volumn 238, Issue 1, 2013, Pages 66-76

  Zhuo, Wenlei ^a   Zhang, Liang ^a   Cai, Lei ^a   Zhu, Bo ^a   Chen, Zhengtang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

bladder cancer; malignancy; meta analysis; polymorphism Experimental; susceptibility; XRCC1 Arg399Gln

Indexed keywords

XRCC1 PROTEIN;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER RISK; CARCINOGENESIS; COLORECTAL CANCER; ESOPHAGUS CANCER; ETHNICITY; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LUNG CANCER; META ANALYSIS; NASOPHARYNX CANCER; PROSTATE CANCER; PROTEIN POLYMORPHISM; PUBLICATION; SENSITIVITY ANALYSIS; SKIN CANCER; SMOKING; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; DNA-BINDING PROTEINS; ETHNIC GROUPS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; SMOKING; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84875591538     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2012.012209     Document Type: Article

References (63)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA-Cancer J Clin 2011;61:69-90
2. Hirao Y, Kim WJ, Fujimoto K. Environmental factors promoting bladder cancer. Curr Opin Urol 2009;19:494-9
3. Gong M, Dong W, An R. Glutathione S-transferase T1 polymorphism contributes to bladder cancer risk: a meta-analysis involving 50 studies. DNA Cell Biol 2012;31:1187-97
4. Jiang Z, Li C, Wang X. Glutathione S-transferase M1 polymorphism and bladder cancer risk: a meta-analysis involving 33 studies. Exp Biol Med (Maywood) 2011;236:723-8
5. Kouidhi S, Rouissi K, Khedhiri S, Ouerhani S, Cherif M, Benammar-Elgaaied A. MTHFR gene polymorphisms and bladder cancer susceptibility: a meta-analysis including race, smoking status and tumour stage. Asian Pac J Cancer Prev 2011;12:2227-32
6. Li D, Liu H, Yan L, Tang Y, Ren J, Xu Z. Lack of association between hOGG1 Ser326Cys polymorphism and the risk of bladder cancer: a meta-analysis. Urol Int 2012;88:88-94
7. Ohnishi S, Murata M, Kawanishi S. Oxidative DNA damage induced by a metabolite of 2-naphthylamine, a smoking-related bladder carcinogen. Jpn J Cancer Res Gann 2002;93:736-43
8. Tang MS, Wang HT, Hu Y, Chen WS, Akao M, Feng Z, Hu W. Acrolein induced DNA damage, mutagenicity and effect on DNA repair. Mol Nutr Food Res 2011;55:1291-300
9. Li GM. A special issue on DNA damage response and genome stability. Cell Biosci 2012;2:4
10. Gonfloni S, Maiani E, Di Bartolomeo C, Diederich M, Cesareni G. Oxidative stress, DNA damage, and c-Abl signaling: at the crossroad in neurodegenerative diseases? Int J Cell Biol 2012;2012: 683097
11. Lovell MA, Markesbery WR. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucl Acids Res 2007;35:7497-504
12. Mutamba JT, Svilar D, Prasongtanakij S, Wang XH, Lin YC, Dedon PC, Sobol RW, Engelward BP. XRCC1 and base excision repair balance in response to nitric oxide. DNA Repair 2011;10:1282-93
13. Ginsberg G, Angle K, Guyton K, Sonawane B. Polymorphism in the DNA repair enzyme XRCC1: utility of current database and implications for human health risk assessment. Mutat Res 2011;727:1-15
14. Tudek B. Base excision repair modulation as a risk factor for human cancers. Mol Aspects Med 2007;28:258-75
15. Lao T, Gu W, Huang Q. A meta-analysis on XRCC1 R399Q and R194W polymorphisms, smoking and bladder cancer risk. Mutagenesis 2008;23:523-32
16. Wang C, Sun Y, Han R. XRCC1 genetic polymorphisms and bladder cancer susceptibility: a meta-analysis. Urology 2008;72:869-72
17. Munafo MR, Clark TG, Flint J. Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res 2004;129:39-44
18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34
19. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513-30
20. Manuguerra M, Matullo G, Veglia F, Autrup H, Dunning AM, Garte S, Gormally E, Malaveille C, Guarrera S, Polidoro S, Saletta F, Peluso M, Airoldi L, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Linseisen J, Boeing H, Trichopoulos D, Kalandidi A, Palli D, Krogh V, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, Lund E, Pera G, Martinez C, Amiano P, Barricarte A, Tormo MJ, Quiros JR, Berglund G, Janzon L, Jarvholm B, Day NE, Allen NE, Saracci R, Kaaks R, Ferrari P, Riboli E, Vineis P. Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions. Carcinogenesis 2007;28:414-22
21. Ryk C, Kumar R, Sanyal S, de Verdier PJ, Hemminki K, Larsson P, Steineck G, Hou SM. Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett 2006;241:142-9
22. Sakano S, Hinoda Y, Sasaki M, Wada T, Matsumoto H, Eguchi S, Shinohara A, Kawai Y, Hara T, Nagao K, Naito K, Matsuyama H. Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer. Pharmacogenomics 2010;11:1377-87
23. Sakano S, Wada T, Matsumoto H, Sugiyama S, Inoue R, Eguchi S, Ito H, Ohmi C, Matsuyama H, Naito K. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer 2006;95:561-70
24. Sanyal S, De Verdier PJ, Steineck G, Larsson P, Onelov E, Hemminki K, Kumar R. Polymorphisms in XPD, XPC and the risk of death in patients with urinary bladder neoplasms. Acta Oncol 2007; 46:31-41
25. Stern MC, Conway K, Li Y, Mistry K, Taylor JA. DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer. Mol Carcinog 2006;45:715-9
26. Covolo L, Placidi D, Gelatti U, Carta A, Scotto Di, Carlo A, Lodetti P, Picciche A, Orizio G, Campagna M, Arici C, Porru S. Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCC1, XRCC3, XPD genetic polymorphisms and coffee consumption: a case-control study. Eur J Epidemiol 2008;23:355-62
27. Andrew AS, Karagas MR, Nelson HH, Guarrera S, Polidoro S, Gamberini S, Sacerdote C, Moore JH, Kelsey KT, Demidenko E Vineis P, Matullo G. DNA repair polymorphisms modify bladder cancer risk: a multi-factor analytic strategy. Hum Heredity 2008; 65:105-18
28. Andrew AS, Nelson HH, Kelsey KT, Moore JH, Meng AC, Casella DP, Tosteson TD, Schned AR, Karagas MR. Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis 2006;27:1030-7
29. Arizono K, Osada Y, Kuroda Y. DNA repair gene hOGG1 codon 326 and XRCC1 codon 399 polymorphisms and bladder cancer risk in a Japanese population. Jpn J Clin Oncol 2008;38:186-91
30. Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis 2005;26:1263-71
31. Figueroa JD, Malats N, Real FX, Silverman D, Kogevinas M, Chanock S, Welch R, Dosemeci M, Tardon A, Serra C, Carrato A, Garcia-Closas R, Castano-Vinyals G, Rothman N, Garcia-Closas M. Genetic variation in the base excision repair pathway and bladder cancer risk. Hum Genet 2007;121:233-42
32. Fontana L, Bosviel R, Delort L, Guy L, Chalabi N, Kwiatkowski F, Satih S, Rabiau N, Boiteux JP, Chamoux A, Bignon YJ, Bernard-Gallon DJ. DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort. Anticancer Res 2008;28:1853-6
33. Gao W, Romkes M, Zhong S, Nukui T, Persad RA, Smith PJ, Branch R, Keohavong P. Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk. Oncol Rep 2010;24:257-62
34. Huang M, Dinney CP, Lin X, Lin J, Grossman HB, Wu X. High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2007;16:84-91
35. Karahalil B, Kocabas NA, Ozcelik T. DNA repair gene polymorphisms and bladder cancer susceptibility in a Turkish population. Anticancer Res 2006;26:4955-8
36. Kelsey KT, Park S, Nelson HH, Karagas MR. A population-based case-control study of the XRCC1 Arg399Gln polymorphism and susceptibility to bladder cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1337-41
37. Matullo G, Dunning AM, Guarrera S, Baynes C, Polidoro S, Garte S, Autrup H, Malaveille C, Peluso M, Airoldi L, Veglia F, Gormally E, Hoek G, Krzyzanowski M, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Linseisen J, Boeing H, Trichopoulou A, Palli D, Krogh V, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, Lund E, Pera G, Martinez C, Dorronsoro M, Barricarte A, Tormo MJ, Quiros JR, Day NE, Key TJ, Saracci R, Kaaks R, Riboli E, Vineis P. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis 2006;27:997-1007
38. Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, Davico L, Piazza A, Vineis P. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer J Int Cancer 2001;92:562-7
39. Matullo G, Guarrera S, Sacerdote C, Polidoro S, Davico L, Gamberini S, Karagas M, Casetta G, Rolle L, Piazza A, Vineis P. Polymorphisms/ haplotypes in DNA repair genes and smoking: a bladder cancer case-control study. Cancer Epidemiol Biomarkers Prev 2005;14(Part 1):2569-78
40. Mittal RD, Mandal RK, Gangwar R. Base excision repair pathway genes polymorphism in prostate and bladder cancer risk in North Indian population. Mech Ageing Dev 2011;133:127-32
41. Ricceri F, Guarrera S, Sacerdote C, Polidoro S, Allione A, Fontana D, Destefanis P, Tizzani A, Casetta G, Cucchiarale G, Vineis P, Matullo G. ERCC1 haplotypes modify bladder cancer risk: a case-control study. DNA Repair 2010;9:191-200
42. Sak SC, Barrett JH, Paul AB, Bishop DT, Kiltie AE. DNA repair gene XRCC1 polymorphisms and bladder cancer risk. BMC Genetics 2007;8:13
43. Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, Wijkstrom H, Larsson P, Kumar R, Hemminki K. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 2004;25:729-34
44. Shen M, Hung RJ, Brennan P, Malaveille C, Donato F, Placidi D, Carta A, Hautefeuille A, Boffetta P, Porru S. Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case-control study in northern Italy. Cancer Epidemiol Biomarkers Prev 2003;12(Part 1):1234-40
45. Stern MC, Umbach DM, van Gils CH, Lunn RM, Taylor JA. DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:125-31
46. Wang M, Qin C, Zhu J, Yuan L, Fu G, Zhang Z, Yin C. Genetic variants of XRCC1, APE1, and ADPRT genes and risk of bladder cancer. DNA Cell Biol 2010;29:303-11
47. Wen H, Ding Q, Fang ZJ, Xia GW, Fang J. Population study of genetic polymorphisms and superficial bladder cancer risk in Han-Chinese smokers in Shanghai. Int Urol Nephrol 2009;41:855-64
48. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE, Lerner S, Dinney CP, Spitz MR. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 2006;78:464-79
49. Stern MC, Umbach DM, Lunn RM, Taylor JA. DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk. Cancer EpidemiolBiomarkers Prev2002;11:939-43
50. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Techn Bull 1999;8:15-7
51. Cui Z, Yin Z, Li X, Wu W, Guan P, Zhou B. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis. BMC Cancer 2012;12:71
52. Wu K, Su D, Lin K, Luo J, Au WW. XRCC1 Arg399Gln gene polymorphism and breast cancer risk: a meta-analysis based on case-control studies. Asian Pac J Cancer Prev 2011;12:2237-43
53. Wei B, Zhou Y, Xu Z, Ruan J, Zhu M, Jin K, Zhou D, Hu Q, Wang Q, Wang Z, Yan Z. XRCC1 Arg399Gln and Arg194Trp polymorphisms in prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis 2011;14:225-31
54. Huang GL, Guo HQ, Yu CY, Liu XY, Li BB, Wu JJ, He ZW. XRCC1 polymorphisms and risk of nasopharyngeal carcinoma: a meta-analysis. Asian Pac J Cancer Prev 2011;12:2329-33
55. Yin M, Tan D, Wei Q. Genetic variants of the XRCC1 gene and susceptibility to esophageal cancer: a meta-analysis. Int J Clin Exp Med 2009;2:26-35
56. Chen B, Zhou Y, Yang P, Wu XT. Polymorphisms of XRCC1 and gastric cancer susceptibility: a meta-analysis. Mol Biol Rep 2012;39:1305-13
57. Zhang H, Li W, Franklin MJ, Dudek AZ. Polymorphisms in DNA repair gene XRCC1 and skin cancer risk: a meta-analysis. Anticancer Res 2011;31:3945-52
58. Liu F, Li B, Wei Y, Yan L, Wen T, Zhao J, Xu M. XRCC1 genetic polymorphism Arg399Gln and hepatocellular carcinoma risk: a meta-analysis. Liver Int 2011;31:802-9
59. Wang B, Wang D, Huang G, Zhang C, Xu DH, Zhou W. XRCC1 polymorphisms and risk of colorectal cancer: a meta-analysis. Int J Colorectal Dis 2010;25:313-21
60. Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Medicine 2005;24:1291-306
61. Yee DS, Ishill NM, Lowrance WT, Herr HW, Elkin EB. Ethnic differences in bladder cancer survival. Urology 2011;78:544-9
62. Jacobs BL, Montgomery JS, Zhang Y, Skolarus TA, Weizer AZ, Hollenbeck BK. Disparities in bladder cancer. Urol Oncol 2012;30:81-8
63. Vispe S, Yung TM, Ritchot J, Serizawa H, Satoh MS. A cellular defense pathway regulating transcription through poly(ADP-ribosyl)ation in response to DNA damage. Proc Natl Acad Sci USA 2000;97:9886-91